CDK4/6 inhibition in early and advanced hormone receptor-positive, HER2-negative breast cancer.
CDK4/6 inhibition in early and advanced hormone receptor-positive, HER2-negative breast cancer. Expert Rev Anticancer Ther. 2025 Apr 29; 1-12.
PMID: 40285528
Treatment, toxicity, and mortality after subsequent breast cancer in female survivors of childhood cancer.
Treatment, toxicity, and mortality after subsequent breast cancer in female survivors of childhood cancer. Nat Commun. 2025 Mar 31; 16(1):3088.
PMID: 40164623
Efficacy of sacituzumab govitecan versus treatment of physician's choice in previously treated HR+ and HER2- mBC: a meta-analysis of TROPiCS-02 and EVER-132-002 trials.
Efficacy of sacituzumab govitecan versus treatment of physician's choice in previously treated HR+ and HER2- mBC: a meta-analysis of TROPiCS-02 and EVER-132-002 trials. Ther Adv Med Oncol. 2025; 17:17588359251320285.
PMID: 40093981
A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer.
A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer. Breast Cancer Res Treat. 2025 May; 211(1):111-119.
PMID: 39928262
Trends and Disparities in the Use of Immunotherapy for Triple-Negative Breast Cancer in the US.
Trends and Disparities in the Use of Immunotherapy for Triple-Negative Breast Cancer in the US. JAMA Netw Open. 2025 Feb 03; 8(2):e2460243.
PMID: 39960669
Hormone Receptor-Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast Cancers.
Hormone Receptor-Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast Cancers. Clin Cancer Res. 2025 Jan 17; 31(2):403-413.
PMID: 39561272
Evaluation of cyclin-dependent kinase 4/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancer.
Evaluation of cyclin-dependent kinase 4/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancer. J Oncol Pharm Pract. 2024 Dec 09; 10781552241305417.
PMID: 39648753
High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration.
High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration. Breast Cancer Res Treat. 2025 Feb; 209(3):563-572.
PMID: 39579248
Hormone Receptor Positive HER2-negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple Negative Breast Cancers.
Hormone Receptor Positive HER2-negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple Negative Breast Cancers. Clin Cancer Res. 2024 Nov 19.
PMID: 39561272
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer.
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer. Cell Rep Med. 2024 Nov 19; 5(11):101799.
PMID: 39510069